Slingshot members are tracking this event:

Vertex's Tezacaftor (VX-661) / ivacaftor in treating Cystic fibrosis - Two Copies of the F508del Mutation PDUFA date under priority review February 28, 2018

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 12, 2018
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Vx-661, Tezacaftor, Cystic Fibrosis, F508del Mutation